Global Percutaneous Aortic Valve Implantation Market to Undergo Significant Growth by 2031 with Increasing Occurrence of Cardiovascular Diseases in the Ageing Population

Percutaneous aortic valve replacement (PAVR) or transcatheter aortic valve replacement (TAVR) is a relatively new method for treating aortic stenosis, however, it has become increasingly common over the past few years. During the PAVR procedure, a replacement valve is crimped onto a catheter and inserted through the femoral artery into the aortic annulus. Quick ventricular pacing is utilized to minimize cardiac output while the prosthesis is placed in the right position following balloon valvuloplasty.

The global percutaneous aortic valve implantation market is growing quickly, mostly due to the rising prevalence of cardiovascular disorders. Cardiovascular disorders impede aortic valve function, resulting in heart attacks and the need for valve replacement surgery. In addition, the increasing number of geriatric patients is propelling the demand for PAVR treatment, as older people are more susceptible to aortic stenosis. The global percutaneous aortic valve implantation market is quickly rising as more patients prefer minimally invasive procedures in their surgeries. All these factors are expanding the growth of the global percutaneous aortic valve implantation market at a rapid pace.

Newest Insights in the Percutaneous Aortic Valve Implantation Market

PAVR is becoming more popular as a result of the rising technological advancements in the PAVR valve. As per a report by Research Dive, the global percutaneous aortic valve implantation market is anticipated to surpass a revenue of $20,132.20 million in the 2022–2031 timeframe. The North America percutaneous aortic valve implantation market is predicted to experience dominant growth in the years to come. This is because of high disposable incomes due to the existence of leading brands enhancing the region's industrial growth and rising number of people suffering from heart disorders in the region.

How are Market Players Responding to the Rising Demand for PAVI?

Market players are greatly investing in pioneering research and inventions, collaborating with other market players, and receiving government permissions for implementing percutaneous aortic valve implantation, to maintain a competitive environment. Some of the foremost players in the percutaneous aortic valve implantation market are Abbott Laboratories, Becton Dickinson and Company, Boston Scientific Corporation, Bracco, JenaValve Technology, Inc., Edwards Lifesciences Corporation, Venus Medtech, Meril Lifesciences, JC Medical Inc., Medtronic Plc., and others. These players are focused on implementing strategies such as mergers and acquisitions, novel developments, collaborations, and partnerships to reach a leading position in the global market. For instance:

• In September 2022, Edwards Lifesciences, an international leader in structural heart disease medical innovation, announced the introduction of the SAPIEN 3 Ultra RESILIA valve, which combines Edwards’ ground-breaking RESILIA tissue technology with the top SAPIEN 3 Ultra transcatheter aortic heart valve.
   
• In October 2022, OpSens , a well-known expert and innovator in the field of optical measurement for medical equipment, announced that the SavvyWire, a novel guidewire for TAVR surgeries, acquired 510(k) regulatory clearance from the U.S. FDA (Food & Drug Administration).
   
• In December 2022, Abbott, a global healthcare company, launched a minimally invasive device available for persons in India with arterial disease insufficiency who are at high or extreme surgical risk. The system is called Navitor. It is the most recent TAVI system of the company.

COVID-19 Impact on the Global Percutaneous Aortic Valve Implantation Market

The unpredicted rise of the coronavirus pandemic in 2020 adversely impacted the global percutaneous aortic valve implantation market. During the pandemic period, the global shutdown had an effect on the capacity to manufacture percutaneous aortic valve implantation devices. In addition, most operations were delayed due to strict government laws requiring only emergency departments (ED) to undertake surgeries. All of these factors contributed to the revenue loss in the global percutaneous aortic valve implantation market. However, TAVI device sales recovered as the percentage of COVID-19 cases declined over time and more procedures were conducted. Hence, the market is expected to observe massive growth in the years to come.